Microgentas Co. develops an exosome extraction reagent for point-of-care molecular diagnostics, specializing in liquid biopsy-based cancer early diagnosis platforms. Their technology enables the isolation and processing of cfDNA and miRNAs from blood, providing products that offer better quality and purity of exosomes.

Vision and Mission: Microgentas Co. aims to create a healthy life for people by contributing to the development of the cancer diagnosis bio industry through liquid biopsy. They are committed to enabling better diagnosis with their sample preparation technology, addressing bottleneck problems in liquid biopsy, including sample preparation and molecular multiplexing assay for various diseases.

Noteworthy Points:

• Established in 2021, Microgentas Co. is a new leading global provider of sample-to-answer solutions.
• Their core technology is a liquid biopsy-based early cancer diagnosis platform that can handle large amounts of samples easily, quickly, and at low prices.
• Microgentas Co.’s DNA extraction equipment, cartridges, and exosome isolation kits are used by research institutes worldwide for molecular diagnosis, genetic testing, and life science research.